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Abstract
Objective—CD14 is a glycosylphosphotidylinositol-(GPI)-anchored membrane glycoprotein
expressed on neutrophils and monocytes/macrophages that also circulates as a soluble form
(sCD14). Despite the well-recognized role of CD14 in inflammation, relatively little is known
about the genetic determinants of sCD14 or the relationship of sCD14 to vascular- and aging-
related phenotypes.
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Methods and Results—We measured baseline levels of sCD14 in over 5,000 European-
American (EA) and African-American (AA) adults 65 years and older from the Cardiovascular
Health Study, who were well-characterized at baseline for atherosclerotic risk factors and
subclinical cardiovascular disease (CVD), and who have been followed for clinical CVD and
mortality outcomes up to 20 years. At baseline, sCD14 generally showed strong positive
correlations with traditional cardio-metabolic risk factors and with subclinical measures of
vascular disease such as carotid wall thickness and ankle-brachial index (independently of
traditional CVD risk factors), and was also inversely correlated with body mass index. In genome-
wide association analyses of sCD14, we (a) confirmed the importance of the CD14 locus on
chromosome 5q21 in EA; (b) identified a novel African ancestry-specific allele of CD14
associated with lower sCD14 in AA; (c) identified a putative novel association in EA of a non-
synonymous variant of PIGC, which encodes an enzyme required for the first step in GPI anchor
biosynthesis. Finally, we show that, like other acute phase inflammatory biomarkers, sCD14
predicts incident CVD, and strongly and independently predicts all-cause mortality in older adults.
Conclusion—CD14 independently predicts risk mortality in older adults.
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INTRODUCTION
CD14 is a glycosylphosphotidylinositol-(GPI)-anchored membrane glycoprotein
constitutively expressed on monocytes/macrophages and neutrophils [1]. Cell-surface or
membrane (m)CD14 binds to lipopolysaccharide (LPS) and other microbial and non-
microbial ligands in the presence of another accessory protein, lipopolysaccharide binding
protein (LBP), resulting in activation of various toll-like receptors and downstream pro-
inflammatory pathway signaling [2,3]. CD14 also exists as a soluble form (sCD14) [4]. In
addition to secretion from liver, sCD14 may be derived by enzymatic cleavage of GPI-
anchored cell membrane-bound CD14 [4-9].
In response to inflammation and infection, interleukin (IL)-6 induces hepatic sCD14
expression; therefore circulating sCD14 is regarded as an acute phase protein [10]. Like
other acute phase proteins, sCD14 levels increase in the setting of acute and chronic
infectious and inflammatory diseases, including atherosclerosis. Similar to membrane-bound
CD14, sCD14 is able to mediate LPS-activation of mCD14-negative cells such as
endothelial and smooth muscle cells [11,12], events that are important for the development
of atherosclerosis and its complications. At higher concentrations, LBP and sCD14 down-
regulate LPS-induced responses [13] by transfer of LPS to lipoproteins for subsequent
removal.
The genetic and environmental determinants of sCD14 are largely unknown, though CD14
expression appears to be at least partially regulated at the genetic level in a cell-type specific
manner. The human CD14 gene on chromosome 5q23-31 contains a common proximal
promoter polymorphism encoding a C/T transition at bp -159 from the major transcription
start site (TSS) that has been associated with circulating sCD14 levels [14,15]. A regulatory
element located further upstream of the CD14 gene is critical for sCD14 expression in
hepatocytes, but not in monocytes [9].
Despite its potential importance for atherosclerosis and other aging-related inflammatory
diseases, sCD14 has not been well-characterized in prospective, population-based studies of
older adults. We therefore measured and analyzed sCD14 in the Cardiovascular Health
Study (CHS), a large cohort of older adults with follow-up for incident CVD and mortality
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for up to 20 years. We first characterized the cross-sectional relationship of sCD14 to other
traditional CVD risk factors and subclinical vascular disease, as well as other inflammatory
CVD biomarkers (fibrinogen, CRP and IL-6). Second, we conducted genome-wide and
CVD candidate gene-centric association scans of sCD14 in the CHS, separately in European
Americans (EA) and African Americans (AA). Finally, we assessed the ability of sCD14
and its main genetic determinants to predict incident CVD and mortality during follow-up.
METHODS
CHS Cohort
The CHS is a prospective population-based cohort study of older adult men and women
recruited from 4 US field centers: Forsyth County, North Carolina; Sacramento County,
California; Washington County, Maryland; and Pittsburgh, Pennsylvania. 5201 participants
(original cohort) were recruited in 1988-1989 [16]. An additional 687 primarily black
participants were recruited in 1992–1993 (minority cohort) for a total cohort of 5888. The
CHS baseline evaluation included demographic, lifestyle and medical histories, physical
examination, fasting blood collection, and assessment of subclinical vascular disease by
carotid ultrasound and ankle-brachial index (ABI) [17]. Informed consent was obtained
using methods approved by institutional review committees at each study site. Genome-wide
genotyping was performed on 2,952 EA and 528 AA unrelated CHS participants with
sCD14 measurements using the Illumina 370CNV platform. Details of the methods for
measurement of plasma biomarkers, genotyping, fine-mapping, ascertainment of clinical
CVD events during follow-up adjudication are described in the online-only Data
Supplement.
Statistical Analysis
Cross-sectional associations between sCD14 and quantitative traits [body mass index (BMI),
lipid levels, fasting glucose, insulin, CRP, IL-6, ABI, and carotid intima media thickness
(IMT)] or binary traits (diabetes, hypertension) were assessed using multiple linear
regression or logistic regression, respectively. Hypertension is defined as systolic BP>140,
diastolic BP>90, or current use of anti-hypertensive medication. CRP and IL-6 were log-
transformed to reduce skewness. To test for genetic associations with sCD14, linear
regression was performed, assuming an additive genetic model, using PLINK [18] for the
genotyped data and Mach2qtl for the imputed data, adjusting for covariates of age, sex, and
the first 10 eigenvectors derived from principal components analysis. For AAs, sCD14 was
analyzed using log-transformed values in the genetic association analyses to assess statistical
significance; means and standard errors were reported from the corresponding
untransformed model for comparisons with EAs. Haplotype frequency estimation and
association analyses were performed using the haplo.stats package for R [19]. Estimation of
sCD14 phenotypic variance explained by genome-wide SNPs was performed using the
Genome-wide Complex Trait Analysis (GCTA) method, as described in the online-only
Data Supplement.
We performed Cox proportional hazards models to test for association between sCD14 (or
other inflammation biomarkers) and risk of incident CVD events or mortality. sCD14 and
other biomarkers were analyzed continuously to estimate the effects of a one standard
deviation (SD) difference in value, as well as categorically using quintiles. The first quintile
represented the reference group. For the continuous analysis, IL-6 and CRP were log
transformed. Persons with adjudicated baseline prevalent disease relevant for each outcome
were excluded prior to analysis. Four Cox-proportional hazard models containing
progressive levels of covariate adjustment were used to assess risk of incident events
associated with baseline sCD14 levels. The first model was minimally adjusted for
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demographic characteristics (age, sex, and race). The second model was additionally
adjusted for traditional CVD risk factors (hypertension, systolic blood pressure diabetes,
smoking, LDL cholesterol). For analysis of mortality, the second model also included
cystatin C, and baseline peripheral artery disease, stroke, coronary heart disease. The third
model included additional adjustment for subclinical vascular disease as assessed by ankle
brachial index (ABI) and internal carotid wall thickness. The fourth model additionally
included adjustment for plasma levels of other inflammation biomarkers, CRP, IL-6 and
fibrinogen. Hazard ratios and 95% confidence intervals (CI) (HRs, 95% CI) for biomarkers
were compared qualitatively with those of other inflammation biomarkers.
Assessment of association between CD14 genotype and CVD in Women’s Health Initiative
To assess the association between CD14 SNP genotype and CVD, we utilized data from a
larger nested case-control sample of incident coronary heart disease and stroke from the
Women’s Health Initiative [20]. The sample included 3,042 MI and 2,222 stroke EA cases
and 296 MI and 251 stroke AA cases. There were 2,943 EA and 295 AA controls without
CHD or stroke. Genotyping and QC of CD14 SNPs was performed using the IBC array at
TGen (Phoenix, Arizona). Logistic regression models were adjusted for traditional risk
factors (age, BMI, smoking, diabetes, hypertension, cholesterol) and principal components
to control for population stratification.
RESULTS
Relationship of sCD14 with baseline CVD risk factors and other inflammation biomarkers
CHS participant characteristics are summarized in Table I in the online-only Data
Supplement, by race. sCD14 levels were approximately normally distributed with a mean ±
S.D. of 1641 ± 348 (range 284 to 4030) ng/mL. sCD14 levels increased with age and
differed significantly by sex (P<0.001) and by race (P<0.001). The mean values in EA
women, EA men, AA women, and AA men were 1714 ± 354, 1596 ± 329, 1551 ± 410, and
1454 ± 392 ng/mL, respectively (Figure 1). The Spearman rank correlation coefficient
between sCD14 and CRP, fibrinogen, and IL-6 were 0.22, 0.21, and 0.17, respectively (all
P<0.001). In age, race, and sex adjusted models, sCD14 was positively correlated with
baseline smoking, diabetes, fasting glucose, hypertension and negatively correlated with
BMI (all P<0.001) (Table 1). The differences in sCD14 by race and sex persisted upon
adjustment for CVD risk factors (Table 1). When adjusted for baseline CHD and CVD risk
factors, sCD14 was strongly and independently associated with other inflammatory and
acute phase proteins, including CRP, IL-6, and fibrinogen, as well as with increased internal
carotid artery wall thickness and decreased ABI (all P<0.001).
Estimation of proportion of sCD14 phenotypic variation explained by genome-wide SNPs
To our knowledge, family-based estimates of sCD14 heritability have not been previously
reported. Therefore, we estimated the amount of phenotypic variance of sCD14 explained by
“distant” genetic relationships between individuals with the CHS EA population by applying
the GCTA method using all genotyped autosomal SNPs. The estimate of sCD14 phenotypic
variance explained by genome-wide SNPs was 33 ± 17% (P = 0.03).
Genome-wide association scan of sCD14 in EA and AA
In the genome-wide association scan of 2,952 EA and 528 AA, two regions, 1q24 and 5q31,
reached genome-wide significance in EA (Figure I in the online-only Data Supplement); the
chromosome 5q31 peak was also genome-wide significant in AA (Figure II in the online-
only Data Supplement). Results for the lead (index) SNPs associated with sCD14 in each
genomic region are summarized in Table 2. In EA, the strongest genome-wide association
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signal was located on chromosome 5q31, centered around the CD14 structural gene. The
5q31 region of association spanned ~500 kb, encompassed 16 additional genes and included
an extended block of LD containing 165 SNPs with P<5 × 10−8 (Figure IIIA in the online-
only Data Supplement). The minor allele at the EA index SNP rs5744441 (MAF=0.22;
imputation quality score = 0.99) was associated with 101 ± 10 ng/mL lower sCD14 (P= 3.0
× 10−23). The rs5744441 SNP is located about 3 kb upstream of CD14.
In the EA GWAS, a second region on chromosome 1q24.3 achieved genome-wide
significance (Table 2 and Figure IV in the online-only Data Supplement). The index SNP
rs1063412 at 1q24.3 is a C/T polymorphism that encodes a Pro266Ser amino acid
substitution within the second exon of PIGC (MAF=0.43). According to the HapMap, the C
allele (Pro266) is the minor allele in European and Asian populations, but is the major allele
in African populations. The C allele (MAF=0.43 in CHS EA) was associated with 48 ± 8 ng/
mL lower sCD14 (P=1.4 × 10−8).
In AA, there was also a genome-wide significant association at the CD14 locus, but the
specific SNPs associated with sCD14 were distinct from those in EA (Table 2 and Figure
IIIB in the online-only Data Supplement). The index SNP in AA rs778584 (MAF=0.31) was
located in the 3′ flanking region and was associated with 128 ng/mL ± 24 higher sCD14 (P=
5.5 × 10−9). The EA index SNP at the CD14 locus rs5744441 was less common
(MAF=0.08) in AA and associated more weakly with sCD14 (Beta=-108 ± 38 ng/mL;
P=0.003). In AA, the PIGC rs1063412 C allele (Pro266) was considerably more common
(MAF=0.83) than in EA. Nonetheless, the PIGC rs1063412 Pro266 variant was not
significantly associated with sCD14 in AA (P=0.95) (Figure V in the online-only Data
Supplement).
Haplotype analysis and fine-mapping of CD14 gene region
To further explore the CD14 gene variants associated with sCD14 in EA and AA, we
utilized denser CD14 genotype data from the IBC array which contains 15 SNPs covering
the CD14 coding, intronic, untranslated, and flanking regions. In EA, the most strongly
associated SNP on the IBC array was rs5744455 (Beta=-101 ± 9.5 ng/mL; P=3.5 × 10−26),
located about 50 bp upstream of the transcription start site. On the basis of 1000 Genomes
CEU data, this SNP is in strong LD with the index GWAS SNP, rs5744441 (LD r2 = 1.0).
After conditioning on rs5744455, P-values for 3 additional SNPs in the CD14 region were
significant at the Bonferroni-adjusted threshold of P<0.003: rs2569191 and rs778584 (which
are in strong LD; r2=0.97) and rs4914, suggesting the possibility of allelic heterogeneity at
the CD14 locus. Together with rs5744455, rs4914 (a synonymous coding variant) and
rs778584 define four common CD14 EA haplotypes (Table 3): Compared to referent
haplotype 1, haplotype 4 (tagged by the minor allele of rs5744455) was associated with
lower sCD14, while haplotype 3 (tagged by the minor allele of rs4914) and haplotype 2
(tagged by the minor allele of rs778584) were each associated with higher sCD14 levels.
In AA, several other SNPs on the IBC array had more significant P-values than the index
SNP from the AA GWAS rs778584. The lead SNP from the IBC analysis was rs5744451
(MAF=0.09), which was associated with 279 ± 36 ng/mL lower sCD14 (P= 1.3 × 10−14).
rs5744451 is located in the 5′ flanking region of CD14. This SNP was not successfully
imputed and hence not included in the GWAS analysis. After conditioning on rs5744451,
three additional CD14 SNPs (rs5744455, rs2569191, and rs778584) had P<0.003. Haplotype
analysis confirmed that rs5744451 tags a second CD14-lowering haplotype that is common
among AA but rare among EA (Table 3).
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Relationship of sCD14 to incident CVD and mortality
Among the 5,462 EA and AA participants with sCD14 measured at the CHS baseline exam,
there were 820 incident MI, 1,547 incident CHD, 945 incident strokes and 3,820 deaths
during the 20-year follow-up period. Of the 3,820 deaths, 1519 were due to cardiovascular
causes and 2,290 were due to non-cardiovascular causes. The relationships between sCD14
and these outcomes are shown in Table 4. When minimally-adjusted for age, sex, race,
baseline sCD14 was associated with increased risk of MI, CHD, stroke, and mortality.
Additional adjustment for traditional risk factors and measures of subclinical vascular
disease attenuated these associations, though the associations with CHD, stroke, and
mortality remained significant. Moreover, the association of sCD14 with mortality and
stroke (but not MI or CHD) was independent of the other studied biomarkers (CRP, IL-6,
fibrinogen). In the fully-adjusted model 4, sCD14 was associated similarly with death due to
cardiovascular causes (HR= 1.13; 95%CI = 1.05 to 1.22; p= 0.001) and death due non-
cardiovascular causes (HR= 1.11; 95%CI = 1.04 to 1.18; p=0.001). Table II in the online-
only Data Supplement shows the association of each inflammation biomarker with mortality
in multivariable models including all the inflammation biomarkers. In these models, sCD14
and IL-6 were each independently associated with mortality, while CRP and fibrinogen were
not. When analyzed categorically, there was a graded, linear increase in mortality risk with
each successive sCD14 quintile. Compared to the bottom quintile, the hazard ratios (95%
confidence intervals) for the 2nd, 3rd, 4th, and 5th quintile were 1.00 (0.87 - 1.14), 1.02
(0.89 - 1.16), 1.12 (0.98 - 1.27), and 1.27 (1.11 - 1.45), respectively. The HRs comparing top
to bottom quintiles for cardiovascular death and non-cardiovascular were 1.26 (95%CI 1.01
-1.57; p=0.04) and 1.32 (95%CI 1.11 - 1.57; p=0.002), respectively.
Among the sCD14-associated SNPs identified in our GWAS, there was no association with
risk of mortality in either ethnicity of CHS (Table III in the online-only Data Supplement).
In CHS, the minor alleles of CD14 rs4914 and rs778584 were each nominally associated
with 1.3 to 1.6 fold increased risk of stroke in AA, while rs778584 was associated with
decreased risk of CHD in EA (P=0.025). However, these results were not significant when
corrected for multiple hypothesis testing. Nor was there significant evidence for association
between CD14 genotype and risk of CHD or stroke in a second, large case-control sample
from WHI (Table IV in the online-only Data Supplement).
DISCUSSION
In a bi-racial population of older adults, we have characterized the epidemiologic and
genetic associations of sCD14, as well as relationships of this inflammatory biomarker to
incident CVD and mortality. Baseline sCD14 was correlated positively with EA ethnicity,
female sex, traditional CVD risk factors (smoking, hypertension, diabetes), and other
inflammatory biomarkers (IL-6, CRP, fibrinogen), and negatively correlated with BMI. We
identified two genome-wide significant sCD14-associated loci, the CD14 structural locus on
chromosome 5q21 and a novel missense variant of PIGC, which encodes an enzyme
required for the first step in GPI anchor biosynthesis. We also showed that sCD14 predicts
incident CVD and mortality in older adults.
Using a combined GWAS and fine-mapping approach, we identified intra- and inter-
population allelic heterogeneity at the CD14 locus, including two new CD14 variants
associated with lower sCD14 levels. The significant, non-redundant variants at the CD14
locus explain 3.7% of the trait variability in EA versus 9.0% in AA. One of these variants
(haplotype 4 tagged by rs5744455 in Table 3) was associated with lower sCD14 in both EA
and AA. rs5744455 may represent a functional variant, as this SNP is located about 50 bp
upstream of the TSS within an ENCODE DNaseI hypersensitivity site in CD14+ monocytes
and promyelocytic cells. DNaseI hypersensitivity sites are characterized by open chromatin
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and tend to be transcriptionally active. The other newly discovered sCD14-lowering variant
was present only among AA (haplotype 5 tagged by rs5744451 in Table 3. Of the SNPs
associated with haplotype 5, rs5744430 lies within a 700 bp hepatocyte-specific enhancer
region located ~6 kb 5′ of the TSS [9,21]. rs5744430 is also located within several
putatively functional genomic elements indicative of chromatin accessibility, including an
ENCODE DNaseI hypersensitivity site, histone methylation and acylation enrichment sites,
and hepatocyte-specific transcription factor binding elements for HNF4A- and FOXA1, as
determined by genome-wide ChIP-Seq [22].
Two other CD14 variants (haplotypes 2 and 3 in Table 3) were associated with higher
sCD14 levels. Haplotype 2 (tagged by rs778584 in our data set) contains the previously
characterized -159 T allele of rs2569190, which is located in the proximal promoter [23].
The CD14 -159 T allele polymorphism increases transcription of CD14 in monocytes by
decreasing binding affinity to the inhibitory Sp3 subunit of an Sp transcription factor site
[15] and has been associated with higher sCD14 concentration [14] as well as greater
density of mCD14 in some studies [24] but not in others [25,26].
Despite the greater burden of CVD risk factors and higher levels of other commonly
measured inflammation biomarkers among AA, we found that levels of sCD14 were lower
in AA than EA. Whether the ethnic differences in sCD14 are due to environmental and/or
genetic factors is uncertain. The CD14 gene locus shows evidence of balancing selection,
particularly among European populations [27], which could be due to its impact on the
magnitude of host immune response to local pathogens. It is also noteworthy that the two
CD14 alleles tagged by rs778584 and rs4914 associated with higher sCD14 are both more
common in EA than AA, while the sCD14-lowering haplotype tagged by rs5744451 is
common only among AA. Assuming independence of SNPs, and an additive genetic model,
differences in allele frequencies between the identified SNPs accounts for approximately
23% of the inter-population differences in sCD14 levels. Therefore, allele frequency
differences at the CD14 locus provide some potential explanation for the higher sCD14
levels observed in EA.
CD14 is one of more than 100 cell-surface proteins anchored to the plasma membrane via
GPI. Assembly of GPI-linked proteins occurs in the endoplasmic reticulum and involves
more than 30 different genes [28]. The first step of the biosynthesis, the transfer of N-
acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol, is mediated by
at least three genes (PIGA, PIGH and PIGC). Somatic mutations in the X-linked gene
phosphatidylinositol glycan class A (PIGA) in hematopoietic stem cells cause paroxysmal
nocturnal hemoglobinuria (PNH), which manifests as bone-marrow failure, hemolytic
anemia, and thrombosis. As a result of the GPI anchoring defect, PNH patients do not
express mCD14 on their monocytes, yet have normal plasma levels of sCD14 [6]. Notably,
the Pro266Ser amino acid substitution encoded by PIGC rs1063412 is predicted to be
functionally deleterious by Condel [29]. The association of higher sCD14 with a functional
coding variant of PIGC suggests that defective GPI anchor synthesis may be a mechanism
that results in increased release of intracellular CD14 into the circulation from myeloid cells.
While the association reached genome-wide significance in EA and is certainly biologically
plausible, verification of the association between PIGC rs1063412 and sCD14 in an
independent EA population is necessary to authenticate the finding.
Germline mutations in GPI anchor genes have been identified in congenital autosomal
recessive disorders that characterized by a diverse range of phenotypes. To our knowledge,
this is the first report of a common, inherited variant of a gene involved in GPI anchor
biosynthesis associated with a complex trait. A recent GWAS identified a SNP located about
70 kb downstream of PIGC associated with waist-hip ratio (WHR) [30]. However, there is
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no LD between the WHR-associated rs1011731 variant and the sCD14-associated PIGC
coding variant. In the current study, we were unable to detect an association between the
PIGC locus and sCD14 in AA. Even though the variant is more common in AA, our AA
sample size was considerably smaller than our EA sample; therefore, power was only 43%
to detect an effect of similar magnitude in AA. Other possible explanations for the lack of
replication in AA include (1) a false-positive result (type I error) or overestimation of the
effect (“winner’s curse”) in EA; (2) effect modification by another genetic or environmental
factor that is differentially expressed between EA and AA; (3) rs1063412 may not be true
causal variant and the frequency of the true causal variant differs between EA and AA and/
or is not well-tagged in AA.
Our results show that sCD14 levels are associated with both subclinical vascular disease
(carotid IMT and ABI) and with risk of future clinical CVD in older adults, independently of
other risk factors. The reason for the negative association between sCD14 and BMI is
unclear, though the inter-relationships between the CD14 system and obesity appear to be
complex. sCD14 can both potentiate and down-regulate responses to LPS. For example,
adipose tissue CD14 gene expression is increased in obese humans [31], while mice
harboring CD14 mutations have decreased body fat [31,32]. In contrast, administration of
exogenous recombinant human sCD14 is associated with decreased visceral fat and
adipocyte inflammatory gene expression in high-fat-fed mice. Another possible explanation
for the paradoxical association with sCD14 observed in CHS is that lower BMI could
constitute a marker for frailty and chronic disease in older adults. Therefore, additional
studies of sCD14 and BMI involving younger populations and longitudinal data on BMI
may be required.
Prior studies of sCD14 and subclinical atherosclerosis have been inconsistent, though most
have included primarily younger and middle-aged subjects [33-36]. In a smaller prospective
European study of healthy middle-aged men, sCD14 levels did not differ between CHD
cases and controls [37]. Despite the association between sCD14 levels and CVD risk in
CHS, we found little evidence of association between CD14 genotype and risk of CHD or
stroke, in samples totaling over 4,000 CHD cases and 3,000 stroke cases. These results are
consistent with those of a recent meta-analysis of previously published studies (11,813 CHD
cases and 6,196 controls) which showed no evidence of association between the CD14
C-159T promoter polymorphism and CHD in Europeans or subjects from India, though a
possible association between -159 T and CHD was observed among East Asians [38].
Several limitations of the current study should be noted. Replication in an independent
sample of EA, and also studies including larger numbers of AA, will be required to validate
the PIGC association and to determine whether the finding is ethnicity-specific. The
remaining phenotypic variability in sCD14 not ascribed to heritable factors or loci identified
in our analyses suggests a contribution of combined effects of rare variants not tagged by
current genotyping arrays, non-additive genetic factors, as well environmental factors.
Therefore, genotyping arrays of even greater density and/or targeted sequencing of the
CD14 locus may ultimately be required to identify the full spectrum of trait-associated
variants. Finally, further study of the inverse relationship of sCD14 with body mass, as well
as generalization of these association findings to younger adults is needed.
In population studies of older adults, serum levels of CRP and IL-6 predict adverse health
outcomes and mortality. Though sCD14 is an acute phase protein, and correlates with CRP
and IL-6, we found that sCD14 and IL-6 were strong and independent risk factors for
mortality in older adults. Accounting for IL-6 and sCD14, there was no association of CRP
or fibrinogen with mortality. sCD14 levels are increased in a number of acute and chronic
inflammatory conditions and higher levels have been associated with disease severity [39],
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including mortality in Gram-negative sepsis [40]. Conversely, in mouse models, CD14
deficiency has been associated with resistance to LPS-induced shock [41], while mice
harboring TLR4 and CD14 mutations have increased bone mineral density, decreased body
fat, greater insulin sensitivity, live long lives and show no evidence of infection [32].
Increasing evidence suggests that pro-inflammatory mediators play a direct role in aging-
related chronic diseases such as atherosclerosis, diabetes and cancer. Whether higher levels
of sCD14 or other inflammatory mediators are directly causal, or indicative of chronic, low-
level infection and other immune alterations in older adults, or simply reflect worsening
subclinical and clinical disease, is difficult to distinguish. Nonetheless, sCD14 may have
potential clinical utility as a marker of aging, disease risk, or disease progression in older
adults.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distribution of soluble CD14 according to ethnicity and sex
Median and inter-quartile range are indicated by the middle band and box edges,
respectively. The whiskers indicate upper and lower adjacent values. Dots indicate values
outlying 1.5 times the IQR above the 75th percentile and 1.5 times the IQR below the 25th
percentile.
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TABLE 1
Association between soluble CD14 and other cardiovascular risk factors and measures of subclinical
cardiovascular disease at the CHS baseline exam





Age (years) 7.13 ± 0.86* 6.60 ± 0.88* 4.34 ± 0.90*
Female sex 119 ± 9.7* 123 ± 9.6* 118 ± 10.3*
African American race −155 ± 13.3* −164 ± 13.5* −185 ± 13.3*
Current smoking 96 ± 15* 84 ± 15* 41 ± 15**
Diabetes 59 ± 10* 66 ± 11* 35 ± 11**
Hypertension 74 ± 10* 78 ± 10* 54 ± 10*
Systolic blood pressure (mm Hg) 0.49 ± 0 .22 0.26 ± 0.22 0.18 ± 0.22
LDL cholesterol (mg/dL) 0.34 ± 0.12 0.44 ± 0.13** 0.43 ± 0.13**
HDL cholesterol (mg/dL) −1.02 ± 0.32** −0.96 ± 0.34** 0.38 ± 0.34
Triglycerides (mg/dL) 17.1 ± 11.1 4.62 ± 11.54 −30 ± 13.4
Glucose (mg/dL) 1.07 ± 0.13* 1.00 ± 0.16* 0.73 ± 0.16*
Insulin (mg/dL) 0.84 ± 0.18* 0.70 ± 0.18* 0.40 ± 0.18
BMI (kg/m2) −4.87 ± 1.03* −4.87 ± 1.03* −13.0 ± 1.12*
Waist circumference (cm) −1.14 ± 0.38** 0.316 ± 0.674 −1.15 ± 0.658
C-reactive protein (g/L) 95 ± 4.5* 101 ± 4.7* 62 ± 6.0*
Interleukin-6 (pg/dL) 117 ± 7.8* 117 ± 8.1* 51 ± 9.3*
Fibrinogen (mg/dL) 1.28 ± 0.069* 1.26 ± 0.070* 0.55 ± 0.085*
Internal carotid wall thickness (mm) 75.6 ± 8.80* 55.6 ± 8.98* 36.7 ± 8.96*
Ankle-brachial index −273 ± 27.8 * −198 ± 28.9* −113 ± 29.1*
Triglycerides, C-reactive protein, and interleukin-6 were natural log-transformed.
Model A: adjusted for age, race, and sex.
Model B: adjusted for age, race, sex, smoking, diabetes, hypertension, systolic blood pressure, BMI.
Model C: adjusted for age, race, sex, smoking, diabetes, hypertension, systolic blood pressure, BMI, LDL cholesterol, HDL cholesterol, C-reactive
protein, interleukin-6, and fibrinogen.
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